TJC 0434
Alternative Names: TJC-0434Latest Information Update: 28 Jun 2023
At a glance
- Originator TaiwanJ Pharmaceuticals
- Class Anti-inflammatories; Antigouts
- Mechanism of Action NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout; Inflammatory bowel diseases
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Gout in Taiwan
- 28 Jun 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Taiwan
- 28 May 2019 Preclinical trials in Gout in Taiwan (unspecified route) (TaiwanJ Pharmaceuticals pipeline, May 2019)